Mitsubishi Tanabe Pharma Corporation
3-2-10, Dosho-machi, Chuo-ku
91 articles with Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma America to Receive Essey Commitment to Cures Award From the ALS Community for Extensive Efforts and Collaboration in ALS Research, Development and Education
ALS Association Golden West Chapter Honors MTPA as a Champion in the Search for ALS Treatments
Mitsubishi Tanabe Pharma Canada is deeply committed to bringing RADICAVA® to people living with ALS, and as part of our commitment we are pleased to announce that RADICAVA will be available in Canada beginning on November 5, 2019.
Phase 3 Clinical Trial Evaluating Continuous Subcutaneous Carbidopa/Levodopa (ND0612) Initiated In The United States For Parkinson's Disease With Motor Fluctuations
Phase 3 BouNDless study investigating the efficacy, safety and tolerability of ND0612, a potential non-surgical, subcutaneous continuous treatment, compared to oral immediate-release carbidopa/levodopa in people with Parkinson's disease experiencing motor fluctuations.
Wendy Agnese, Pharm.D., Director of Medical Affairs, MTPA , will present details regarding REFINE-ALS study design methodology and goals to identify and measure specific biomarkers and clinical assessments in people with amyotrophic lateral sclerosis
Proprietary Technology Platform to Assess Biomarker Panels in People with ALS
Post-Hoc Analyses of RADICAVA® (edaravone) Studies Show Phase 3 Study Design Minimized ALS Heterogeneity to Improve Trial Efficiency
Strategic Inclusion Criteria Enabled Detection of Efficacy Intended to be Generalizable to Larger ALS Population
BioInvent International AB announced that it has received a €0.75 million milestone payment under its collaboration with Mitsubishi Tanabe Pharma Corporation in connection with enrollment of the first patient in a Phase II clinical trial of an antibody identified from BioInvent's proprietary n-CoDeR® antibody library.
Salix Enters Into Exclusive License Agreement With Mitsubishi Tanabe Pharma To Develop And Commercialize Late Stage Investigational S1P Modulator For The Treatment Of Inflammatory Bowel Disease
Investigational Oral Compound to Strengthen Salix's Expanding Pipeline
Mitsubishi Tanabe Pharma America Announces Names Of Teens And Young Adults Chosen For Inclusion In ALSO US™ Initiative
Program Fosters Use of Original Written and Visual Art to Share Experiences with Amyotrophic Lateral Sclerosis (ALS)
3/8/2019Perhaps the biggest mover and shaker announcement this week was the unexpected resignation of Scott Gottlieb, commissioner of the U.S. Food and Drug Administration. Gottlieb will leave his post later this month to spend more time with his family.
HitGen and Mitsubishi Tanabe Pharma Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration
HitGen Ltd announced that the company has entered into a drug discovery research collaboration with Mitsubishi Tanabe Pharma Corporation (President and CEO: Masayuki Mitsuka; Headquarters: Osaka; “MTPC”) to identify novel small molecule leads for targets of interest.
Mitsubishi Tanabe Pharma America To Showcase ALS Research At 29th International Symposium On ALS/MND In Glasgow
Presentations Highlight Commitment to Further ALS Research and Treatment
Mitsubishi Tanabe Pharma Group Companies To Present New Data On Investigational Oral Formulation Of Edaravone For ALS At 29th International Symposium On ALS/MND
Initial Study Results Show a Single Oral Dose is Expected to Have Similar Pharmacokinetic Parameters as IV Infusion
Mitsubishi Tanabe Pharma Canada Announces Canadian Authorization Of RADICAVA™ (edaravone) To Treat ALS
Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA) today announced that Health Canada has granted market authorization of RADICAVA™ (edaravone) as an intravenous infusion treatment for amyotrophic lateral sclerosis (ALS), a rapidly progressive, neurodegenerative disease.1,2
Once again, Amgen is accepting submissions for the 2018 Amgen-LabCentral Golden Ticket competition.
Privately-held ITF Pharma snagged regulatory approval for Tiglutik, a liquid formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
ALS is a progressive neurodegenerative disease that affects neurons in the brain and the spinal cord. The disease is usually fatal within two to five years of diagnosis. While there is no cure for the disease, multiple companies are working on treatments hoping to be the first to provide a viable...
With a Strong Focus on ALS Patients, Mitsubishi Tanabe Pharma America Works to Increase Access an...
5/31/2018It has been one year since Mitsubishi Tanabe Pharma America’s Radicava was approved as the first treatment for amyotrophic lateral sclerosis (ALS) in more than 20 years. Since its approval, MTPA has been aggressive in its efforts to get the medication in the hands of ALS patients.
Clinigen Group plc has partnered with Mitsubishi Tanabe Pharma Corporation (‘MTPC’), to initiate a Managed Access Program (also known as an Early Access Program) in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (‘ALS’).
Mitsubishi Tanabe Pharma America Announces ALS Presentations At American Academy Of Neurology Annual Meeting
Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced presentations on amyotrophic lateral sclerosis (ALS) at the 70th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.